BRIEF-Standard Biotools Announces Sale Of Mass Cytometry Business And Illumina’S Buyout Of Contingent Payments To Advance Merger With Treeline Biosciences
Reuters2026/07/28 12:13July 28 (Reuters) - Standard BioTools Inc LAB.O:
STANDARD BIOTOOLS ANNOUNCES SALE OF MASS CYTOMETRY BUSINESS AND ILLUMINA’S BUYOUT OF CONTINGENT PAYMENTS TO ADVANCE MERGER WITH TREELINE BIOSCIENCES
STANDARD BIOTOOLS - TO SELL MASS CYTOMETRY BUSINESS TO MULTIPLEX BIO
STANDARD BIOTOOLS - MASS CYTOMETRY BUSINESS SALE VALUED AT UP TO $10 MILLION
Source text: ID:nGNX8sbBPh
Further company coverage: LAB.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Mark Cuban predicts computer chips will be the next hot asset, shifts focus from Bitcoin
Finance Expert Has a Message for XRP Holders: Is This Simply Market Volatility?
PancakeSwap v3 hosts $3B in spot DEX trading volume for tokenized stocks
Valkyrie joins race for spot bitcoin ETF with Wednesday SEC filing
Crypto prices
More
